Lybrel To Launch In July Following FDA Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth’s oral contraceptive is the first continuous-use product without a placebo phase or pill-free interval.
You may also be interested in...
Barr Seeks FDA Approval Of Low-Dose Extended-Cycle Contraceptive Lo Seasonique
FDA grants Lo Seasonique an Oct. 24 action date.
Barr Seeks FDA Approval Of Low-Dose Extended-Cycle Contraceptive Lo Seasonique
FDA grants Lo Seasonique an Oct. 24 action date.
Wyeth Raises 2007 Earnings Guidance, Buoyed By Biologics Revenues
Growth is led by 27 percent increase in revenue from biologics compared to the second quarter of 2006.